Serum concentrations of nitric oxide, tumor necrosis factor (TNF)-α and TNF soluble receptors in women with overweight and obesity

被引:96
作者
Olszanecka-Glinianowicz, M [1 ]
Zahorska-Markiewicz, B [1 ]
Janowska, J [1 ]
Zurakowski, A [1 ]
机构
[1] Silesian Univ, Sch Med, Dept Pathophysiol, PL-40752 Katowice, Poland
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2004年 / 53卷 / 10期
关键词
D O I
10.1016/j.metabol.2004.07.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aims of the present study was to examine how overweight and obesity affect serum concentrations nitric oxide (NO) metabolites and to determine whether there is association between serum concentrations tumor necrosis factor (TNF)-alpha and TNF soluble receptors (sTNF-R) in subjects with overweight and obesity. The study groups involved 154 women: 102 obese (81 obese with body mass index [BMI] 30 to 40 kg/m(2) and 21 obese with BMI >40 kg/m(2)), 24 overweight patients, and 28 lean controls. Serum concentrations of NO metabolites and of TNF-alpha and its soluble receptors (sTNF-R1, sTNFR-2) were measured by enzyme-linked immunosorbent assay (ELISA) kits. Serum concentration of insulin was measured by radioimmunoassay (RIA). Plasma glucose, cholesterol, high-density lipoprotein (HDL)-cholesterol, and triglicerydes were determined by enzymatic procedure. Body composition was determined by impedance analysis using Bodystat (Douglas, British Isles). Serum concentrations of NO in the overweight group (35.1 +/- 12.1 mumol/L) and the obese groups with BMI 30 to 40 kg/m(2) (32.8 +/- 9.3 mumol/L) and with BMI greater than 40 kg/m(2) (33.3 +/- 8.5 mumol/L) were significantly higher when compared to controls (28.2 +/- 8.1 mumol/L): P < .05; P < .01, and P < .01, respectively. There was no difference in levels of NO between the overweight group and both obese groups. Serum concentration of TNF-alpha was also significantly higher in the group with overweight (6.5 +/- 3.1 pg/mL), in the obese group with BMI 30 to 40 kg/m(2) (6.8 +/- 3.1 pg/mL), and in the obese group with BMI greater than 40 kg/m(2) (7.4 +/- 2.6 pg/mL) when compared to controls (2.9 +/- 2.2 pg/mL): P < .00005; P < .00005, and P < .0000001, respectively. However, serum concentrations of sTNF-R1 and -R2 did not differ significantly between the overweight group, both obese groups, and controls. In conclusion, we observed increased serum concentrations of TNF-alpha and NO in overweight and obese women. It seems that there is an association between serum concentrations of TNF-alpha and NO; however, this relationship depends on the degree of obesity. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:1268 / 1273
页数:6
相关论文
共 23 条
[1]  
Choi JW, 2001, CLIN CHEM, V47, P1106
[2]   SOLUBLE RECEPTORS FOR TUMOR-NECROSIS-FACTOR IN CLINICAL LABORATORY DIAGNOSIS [J].
DIEZRUIZ, A ;
TILZ, GP ;
ZANGERLE, R ;
BAIERBITTERLICH, G ;
WACHTER, H ;
FUCHS, D .
EUROPEAN JOURNAL OF HAEMATOLOGY, 1995, 54 (01) :1-8
[3]   Soluble tumor necrosis Factor-α receptors in young obese subjects with normal and impaired glucose tolerance [J].
Dzienis-Straczkowska, S ;
Straczkowski, M ;
Szelachowska, M ;
Stepien, A ;
Kowalska, I ;
Kinalska, I .
DIABETES CARE, 2003, 26 (03) :875-880
[4]  
Elizalde M, 2000, J LIPID RES, V41, P1244
[5]  
Ferlito S, 1997, Minerva Cardioangiol, V45, P553
[6]   Plasma concentrations of soluble TNF-alpha receptors in obese subjects [J].
Hauner, H ;
Bender, M ;
Haastert, B ;
Hube, F .
INTERNATIONAL JOURNAL OF OBESITY, 1998, 22 (12) :1239-1243
[7]   Molecular mechanisms regulating hormone-sensitive lipase and lipolysis [J].
Holm, C ;
Osterlund, T ;
Laurell, H ;
Contreras, JA .
ANNUAL REVIEW OF NUTRITION, 2000, 20 :365-+
[8]   ADIPOSE EXPRESSION OF TUMOR-NECROSIS-FACTOR-ALPHA - DIRECT ROLE IN OBESITY-LINKED INSULIN RESISTANCE [J].
HOTAMISLIGIL, GS ;
SHARGILL, NS ;
SPIEGELMAN, BM .
SCIENCE, 1993, 259 (5091) :87-91
[9]   THE EXPRESSION OF TUMOR-NECROSIS-FACTOR IN HUMAN ADIPOSE-TISSUE - REGULATION BY OBESITY, WEIGHT-LOSS, AND RELATIONSHIP TO LIPOPROTEIN-LIPASE [J].
KERN, PA ;
SAGHIZADEH, M ;
ONG, JM ;
BOSCH, RJ ;
DEEM, R ;
SIMSOLO, RB .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (05) :2111-2119
[10]   Nitric oxide synthases: Which, where, how, and why? [J].
Michel, T ;
Feron, O .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (09) :2146-2152